Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Leap Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MASS. , OCT. 9, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT LED BY WINKLEVOSS CAPITAL RAISING $58,888,888 IN CASH TO INITIATE A DIGITAL ASSET TREASURY STRATEGY.

LEAP THERAPEUTICS ANNOUNCES CLOSING OF $58.88 MILLION PRIVATE PLACEMENT IN CASH LED BY WINKLEVOSS CAPITAL TO INITIATE A DIGITAL ASSET TREASURY STRATEGY

CAMBRIDGE, MASS. , OCT. 6, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED $58,888,888 IN CASH COMMITMENTS FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY ("PIPE") OFFERING LED BYWINKLEVOSS CAPITAL TO INITIATE A DIGITAL ASSET TREASURY STRATEGY.

LEAP THERAPEUTICS ANNOUNCES $58.88 MILLION PRIVATE PLACEMENT IN CASH COMMITMENTS LED BY WINKLEVOSS CAPITAL TO INITIATE A DIGITAL ASSET TREASURY STRATEGY

CAMBRIDGE, MASS. , SEPT. 25, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS, INC. (NASDAQ: LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED IT WILL PRESENT THE FINAL CLINICAL RESULTS FROM PART B OF THE DEFIANCE STUDY (NCT05480306), A PHASE 2 STUDY OF SIREXATAMAB (DKN-01), AN ANTI-DKK1 MONOCLONAL ANTIBODY, IN COMBINATION WITH BEVACIZUMAB AND CHEMOTHERAPY (SIREXATAMAB ARM) COMPARED TO BEVACIZUMAB AND CHEMOTHERAPY (CONTROL ARM) IN PATIENTS WITH ADVANCED MICROSATELLITE STABLE (MSS) COLORECTAL CANCER (CRC) WHO HAVE RECEIVED ONE PRIOR SYSTEMIC THERAPY FOR ADVANCED DISEASE.

LEAP THERAPEUTICS TO PRESENT FINAL CLINICAL DATA FROM PART B OF THE DEFIANCE STUDY AT THE ESMO CONGRESS 2025

CAMBRIDGE, MASS. , AUG. 14, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS, INC. (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

LEAP THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

UPDATED DATA FROM DEFIANCE STUDY CONTINUE TO DEMONSTRATE STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PFS AMONG THE DKK1-HIGH, VEGF-NAVE AND LIVER METASTASIS SUBGROUPS BOARD OF DIRECTORS HAS INITIATED PROCESS TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE CAMBRIDGE, MASS. , JUNE 23, 2025 /PRNEWSWIRE/ --LEAP THERAPEUTICS, INC. (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY REPORTED UPDATED RESULTS FROM PART B OF THE DEFIANCE STUDY (NCT05480306), A PHASE 2 STUDY OF SIREXATAMAB (DKN-01), AN ANTI-DKK1 MONOCLONAL ANTIBODY, IN COMBINATION WITH BEVACIZUMAB AND CHEMOTHERAPY (SIREXATAMAB ARM) COMPARED TO BEVACIZUMAB AND CHEMOTHERAPY (CONTROL ARM) IN PATIENTS WITH ADVANCED MICROSATELLITE STABLE (MSS) COLORECTAL CANCER (CRC) WHO HAVE RECEIVED ONE PRIOR SYSTEMIC THERAPY FOR ADVANCED DISEASE.

LEAP THERAPEUTICS REPORTS UPDATED CLINICAL DATA FROM SIREXATAMAB COLORECTAL CANCER STUDY AND ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES

CAMBRIDGE, MASS. , MAY 13, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS, INC. (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025.

LEAP THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

FL-501 FULLY RESTORED BODY COMPOSITION AND REVERSED KEY INDICATORS OF CACHEXIA IN PRECLINICAL MODELS FINDINGS CONFIRM GDF-15'S ROLE IN CACHEXIA AND SUPPORT ADVANCING FL-501 INTO THE CLINIC CAMBRIDGE, MASS. , APRIL 25, 2025 /PRNEWSWIRE/ -- LEAP THERAPEUTICS, INC. (NASDAQ:LPTX), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TARGETED AND IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED IT WILL PRESENT PRECLINICAL DATA OF FL-501 IN A POSTER PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING TAKING PLACE APRIL 25-30 IN CHICAGO, ILLINOIS.

LEAP THERAPEUTICS TO PRESENT PRECLINICAL DATA OF FL-501, A NOVEL GDF-15 NEUTRALIZING ANTIBODY, AT THE AACR 2025 ANNUAL MEETING

VIRTUAL KOL EVENT ON WEDNESDAY, APRIL 23, 2025, AT 2:30 P.M. ET CAMBRIDGE, MASS.

LEAP THERAPEUTICS TO HOST VIRTUAL KOL EVENT TO DISCUSS SIREXATAMAB (DKN-01) IN SECOND-LINE PATIENTS WITH ADVANCED MICROSATELLITE STABLE COLORECTAL CANCER

LEAP TO HOST A CONFERENCE CALL TO PRESENT UPDATED CRC CLINICAL DATA TODAY, MARCH 26, 2025, AT 8:00 A.M. ET CAMBRIDGE, MASS.

LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

UPDATED DATA CONFIRMS STATISTICALLY SIGNIFICANT 32% HIGHER ORR AND 3.5 MONTH LONGER PFS IN SECOND-LINE CRC PATIENTS WITH HIGH DKK1 LEVELS TREATED WITH SIREXATAMAB PLUS BEVACIZUMAB AND CHEMOTHERAPY STATISTICALLY SIGNIFICANT 22% HIGHER ORR AND 2.6 MONTH LONGER PFS IN PATIENTS WHO HAD NOT HAD PRIORANTI-VEGF THERAPY LEAP TO HOST A CONFERENCE CALL TO PRESENT CLINICAL DATA TODAY, MARCH 26, 2025, AT 8:00 A.M. ET CAMBRIDGE, MASS.

Leap Therapeutics, Inc.

LPTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Leap Therapeutics, Inc.

LPTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LPTX